Bachem Holding AG Class B (CH:BANB)
:BANB
Want to see CH:BANB full AI Analyst Report?
BANB Stock Chart & Stats
CHF70.15
CHF0.05(0.09%)
At close: 4:00 PM EST
CHF70.15
CHF0.05(0.09%)
Day’s Range― - ―
52-Week RangeCHF48.20 - CHF83.25
Previous CloseN/A
Volume38.68K
Average Volume (3M)109.83K
Market Cap
CHF5.79B
Enterprise ValueCHF6.05B
Total Cash (Recent Filing)CHF30.99M
Total Debt (Recent Filing)CHF57.39M
Price to Earnings (P/E)11.4
Beta0.78
Next Earnings
Jul 21, 2026EPS Estimate
0.73Next Dividend Ex-DateN/A
Dividend Yield1.43%
Share Statistics
EPS (TTM)1.99
Shares Outstanding75,000,000
10 Day Avg. Volume97,857
30 Day Avg. Volume109,830
Financial Highlights & Ratios
PEG Ratio1.27
Price to Book (P/B)3.08
Price to Sales (P/S)6.46
P/FCF Ratio-93.15
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF84.20Price Target Upside20.03% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)2.39
Revenue Forecast (FY)CHF950.60M
Bulls Say, Bears Say
Bulls Say
Very Conservative Balance Sheet; Minimal LeverageExtremely low leverage provides durable financial flexibility, reducing bankruptcy and refinancing risk over the medium term. A strong equity base and minimal debt support investment in capacity, long-term supply contracts and R&D without reliance on cyclical capital markets, aiding stability.
Solid Profitability With Steady Multi-year Revenue GrowthConsistent top-line expansion combined with healthy net margins indicates a resilient earnings profile. This durability supports reinvestment, funds commercial-scale projects and underpins returns to shareholders, while providing a buffer versus cyclical biotech customer demand shifts.
Business Model: Recurring CDMO And Long-term Commercial SupplyA mixed model of development services plus recurring commercial supply creates multi-year revenue visibility when projects convert to commercial scale. Long-term supply contracts and regulatory qualification for peptide APIs create switching costs and durable customer relationships.
Bears Say
Persistent Negative Free Cash Flow Since 2021Repeated negative free cash flow over multiple years signals that capex, working-capital or investment needs exceed operating cash generation. Over the medium term this can constrain self-funded growth, increase reliance on external financing and limit durable free-cash availability.
Inconsistent Conversion Of Earnings To Operating CashVolatile cash conversion undermines predictability of internally generated funds for capex and contract-backed supply commitments. Structural working-capital swings or project timing can stress liquidity planning and make financing needs less predictable across 2-6 month horizons.
Gradual Margin Drift From 2021–2022 LevelsSustained margin erosion suggests cost pressures, pricing dynamics or mix shifts toward lower-margin clinical work. If persistent, this reduces cash generation potential and return metrics, constraining durable profitability and the company’s ability to finance expansion internally.
Bachem Holding AG News
BANB FAQ
What was Bachem Holding AG Class B’s price range in the past 12 months?
Bachem Holding AG Class B lowest stock price was CHF48.20 and its highest was CHF83.25 in the past 12 months.
What is Bachem Holding AG Class B’s market cap?
Bachem Holding AG Class B’s market cap is CHF5.79B.
When is Bachem Holding AG Class B’s upcoming earnings report date?
Bachem Holding AG Class B’s upcoming earnings report date is Jul 21, 2026 which is in 68 days.
How were Bachem Holding AG Class B’s earnings last quarter?
Bachem Holding AG Class B released its earnings results on Mar 12, 2026. The company reported CHF1.32 earnings per share for the quarter, beating the consensus estimate of CHF0.88 by CHF0.44.
Is Bachem Holding AG Class B overvalued?
According to Wall Street analysts Bachem Holding AG Class B’s price is currently Undervalued.
Does Bachem Holding AG Class B pay dividends?
Bachem Holding AG Class B pays a Annually dividend of CHF0.85 which represents an annual dividend yield of 1.43%. See more information on Bachem Holding AG Class B dividends here
What is Bachem Holding AG Class B’s EPS estimate?
Bachem Holding AG Class B’s EPS estimate is 0.73.
How many shares outstanding does Bachem Holding AG Class B have?
Bachem Holding AG Class B has 75,000,000 shares outstanding.
What happened to Bachem Holding AG Class B’s price movement after its last earnings report?
Bachem Holding AG Class B reported an EPS of CHF1.32 in its last earnings report, beating expectations of CHF0.88. Following the earnings report the stock price went up 7.734%.
Which hedge fund is a major shareholder of Bachem Holding AG Class B?
Currently, no hedge funds are holding shares in CH:BANB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Bachem Holding AG Class B
Bachem Holding AG provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide. The company engages in the development, production, and regulatory support of peptide active pharmaceutical ingredients, such as peptide and oligonucleotide new chemical entities (NCEs). It also offers commercial NCEs and generics; and project management, quality and regulatory, analytical, good manufacturing practice production, research grade production, and supply and vertical integration services. The company was founded in 1971 and is headquartered in Bubendorf, Switzerland. Bachem Holding AG operates as a subsidiary of Ingro Finanz AG.
BANB Stock 12 Month Forecast
Average Price Target
CHF84.20
▲(20.03% Upside)
Technical Analysis
Lonza Group Ltd
―
Siegfried Holding AG
―
Ypsomed Holding AG
―
PolyPeptide Group AG
―
Galenica AG
―
Options Prices
Currently, No data available
---